– USA, CA – Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy to treat complex calcified cardiovascular disease, today announced the appointment of Sara Toyloy to its Board of Directors and the Audit Committee.
“I am delighted to welcome Sara to our Board of Directors,” said CEO, Doug Godshall. “Her background and depth of experience in regulatory and clinical affairs within the medical technology sector are a perfect complement to our current Directors. Sara will be an invaluable resource and addition to Shockwave as we continue to build our business and increase access to IVL for patients across the globe.”
About Sara Toyloy
Sara Toyloy, who is a recognized leader in the medical device industry with over 30 years of professional experience in regulatory affairs and clinical research, currently serves as President of Fabrica Consulting, LLC, a consulting firm that she founded in 2020 to provide global regulatory and clinical trial strategies to support the medical device approval process. Ms. Toyloy has substantive experience in the development, execution, and negotiation of global regulatory agency approval strategies. Throughout her career, Ms. Toyloy has served in multiple successive positions from Pre-Clinical Research Associate to President. In her most recent role, Ms. Toyloy served as President, New Therapies, and Chief Regulatory Officer of Elixir Medical Corporation, a company focused on delivering innovative solutions that combine state-of-the-art medical devices with advanced pharmaceuticals. Before joining Elixir Medical, Ms. Toyloy held several executive management positions including EVP of Biosensors International, VP, Regulatory and Clinical Affairs at Medtronic Vascular, and Director of Regulatory Affairs and Clinical Research at Guidant Corporation.
“I am honored and excited to join the Shockwave Medical Board of Directors,” said Ms. Toyloy. “I look forward to joining this extraordinary team and to helping Shockwave continue the important work of transforming the treatment of calcified coronary disease for patients throughout the world.”
Ms. Toyloy holds a B.S. Degree in Biological Sciences from California State University, Hayward.
About Shockwave Medical, Inc.
Shockwave is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. Shockwave aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy. IVL is a minimally invasive, easy-to-use, and safe way to significantly improve patient outcomes.
For more information: https://shockwavemedical.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.